Jump Financial, LLC Fate Therapeutics Inc Transaction History

Jump Financial, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $672,672 - $1.2 Million	-215,600 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $702,856 - $1.53 Million	215,600 New	215,600 $707,000
Q2 2023 Oct 21, 2024	BUY	$4.76 - $6.59 $498,148 - $689,663	104,653 Added 40.66%	362,053 $1.72 Million
Q2 2023 Aug 07, 2023	BUY	$4.76 - $6.59 $498,148 - $689,663	104,653 Added 40.66%	362,053 $1.72 Million
Q1 2023 Oct 21, 2024	BUY	$4.24 - $11.12 $177,232 - $464,815	41,800 Added 19.39%	257,400 $1.47 Million
Q1 2023 May 03, 2023	BUY	$4.24 - $11.12 $694,982 - $1.82 Million	163,911 Added 175.33%	257,400 $1.47 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $29,372 - $70,989	2,979 Added 3.29%	93,489 $943,000
Q3 2022 Nov 07, 2022	SELL	$21.04 - $36.06 $33,874 - $58,056	-1,610 Reduced 1.75%	90,510 $2.03 Million
Q2 2022 Aug 09, 2022	BUY	$17.78 - $42.39 $801,913 - $1.91 Million	45,102 Added 95.92%	92,120 $2.28 Million
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $1.4 Million - $2.83 Million	47,018 New	47,018 $1.82 Million
Q4 2021 Feb 10, 2022	SELL	$47.84 - $64.34 $1.44 Million - $1.94 Million	-30,121 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $1.79 Million - $2.88 Million	30,121 New	30,121 $1.79 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.